|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu X, Liu B, Li R, Wang F, Wang N, Zhang
M, Bai Y, Wu J, Liu L, Han D, et al: miR-146a-5p plays an oncogenic
role in NSCLC via suppression of TRAF6. Front Cell Dev Biol.
8:8472020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hellmann MD, Li BT, Chaft JE and Kris MG:
Chemotherapy remains an essential element of personalized care for
persons with lung cancers. Ann Oncol. 27:1829–1835. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sarin N, Engel F, Kalayda GV, Mannewitz M,
Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde
U and Frötschl R: Cisplatin resistance in non-small cell lung
cancer cells is associated with an abrogation of cisplatin-induced
G2/M cell cycle arrest. PLoS One. 12:e1810812017. View Article : Google Scholar
|
|
5
|
Mazzu YZ, Armenia J, Chakraborty G,
Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu
X, Zhao H, et al: A novel mechanism driving poor-prognosis prostate
cancer: Overexpression of the DNA repair gene, ribonucleotide
reductase small subunit M2 (RRM2). Clin Cancer Res. 25:4480–4492.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng S, Yi L, Liao L, Bin Y, Qu W and Hu
H: Circ_0008285 knockdown represses tumor development by
miR-384/RRM2 axis in hepatocellular carcinoma. Ann Hepatol.
27:1007432022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Q, Guo L, Qi H, Lou M, Wang R, Hai B,
Xu K, Zhu L, Ding Y, Li C, et al: A MYBL2 complex for RRM2
transactivation and the synthetic effect of MYBL2 knockdown with
WEE1 inhibition against colorectal cancer. Cell Death Dis.
12:6832021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang CC, Lin CC, Wang CH, Huang CC, Ke
TW, Wei PL, Yeh KT, Hsu KC, Hsu NY and Cheng YW: MiR-211 regulates
the expression of RRM2 in tumoral metastasis and recurrence in
colorectal cancer patients with a k-ras gene mutation. Oncol Lett.
15:8107–8117. 2018.PubMed/NCBI
|
|
10
|
Liu Q, Song C, Li J, Liu M, Fu L, Jiang J,
Zeng Z and Zhu H: E2F2 enhances the chemoresistance of pancreatic
cancer to gemcitabine by regulating the cell cycle and upregulating
the expression of RRM2. Med Oncol. 39:1242022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu H, Lu S, Yang D, Zhang L, Ye J, Li M
and Hu W: MiR-20a-5p regulates gemcitabine chemosensitivity by
targeting RRM2 in pancreatic cancer cells and serves as a predictor
for gemcitabine-based chemotherapy. Biosci Rep. 39:BSR201813742019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen P, Wu JN, Shu Y, Jiang HG, Zhao XH,
Qian H, Chen K, Lan T, Chen CG and Li J: Gemcitabine resistance
mediated by ribonucleotide reductase M2 in lung squamous cell
carcinoma is reversed by GW8510 through autophagy induction. Clin
Sci (Lond). 132:1417–1433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen CW, Li Y, Hu S, Zhou W, Meng Y, Li Z,
Zhang Y, Sun J, Bo Z, DePamphilis ML, et al: DHS
(trans-4,4′-dihydroxystilbene) suppresses DNA replication and tumor
growth by inhibiting RRM2 (ribonucleotide reductase regulatory
subunit M2). Oncogene. 38:2364–2379. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue T, Wang L, Li Y, Song H, Chu H, Yang
H, Guo A and Jiao J: SiRNA-mediated RRM2 gene silencing combined
with cisplatin in the treatment of epithelial ovarian cancer in
vivo: An experimental study of nude mice. Int J Med Sci.
16:1510–1516. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Wang J, Yao R and Wang L: Small
interfering RNA (siRNA)-mediated silencing of the M2 subunit of
ribonucleotide reductase: A novel therapeutic strategy in ovarian
cancer. Int J Gynecol Cancer. 23:659–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Meng L, Wang XW, Ma GY and Chen
JH: Expression of RRM1 and RRM2 as a novel prognostic marker in
advanced non-small cell lung cancer receiving chemotherapy. Tumour
Biol. 35:1899–1906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng Y, Chen X, Huang C, Song J, Feng S,
Chen X and Zhou R: Screening and validation of significant genes
with poor prognosis in pathologic stage-I lung adenocarcinoma. J
Oncol. 2022:37940212022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grossi F, Dal Bello MG, Salvi S, Puzone R,
Pfeffer U, Fontana V, Alama A, Rijavec E, Barletta G, Genova C, et
al: Expression of ribonucleotide reductase subunit-2 and
thymidylate synthase correlates with poor prognosis in patients
with resected stages I–III non-small cell lung cancer. Dis Markers.
2015:3026492015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
DasGupta R, Kaykas A, Moon RT and Perrimon
N: Functional genomic analysis of the Wnt-wingless signaling
pathway. Science. 308:826–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brown AM: Canonical Wnt signaling:
High-throughput RNAi widens the path. Genome Biol. 6:2312005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu H and Li B: MicroRNA-582-3p targeting
ribonucleotide reductase regulatory subunit M2 inhibits the
tumorigenesis of hepatocellular carcinoma by regulating the
Wnt/β-catenin signaling pathway. Bioengineered. 13:12876–12887.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Peng J, Zhou Y, Xie B and Wang J:
Silencing RRM2 inhibits multiple myeloma by targeting the
Wnt/beta-catenin signaling pathway. Mol Med Rep. 20:2159–2166.
2019.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang YW, Jones TL, Martin SE, Caplen NJ
and Pommier Y: Implication of checkpoint kinase-dependent
up-regulation of ribonucleotide reductase R2 in DNA damage
response. J Biol Chem. 284:18085–18095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabral-Pacheco GA, Garza-Veloz I,
Castruita-De LRC, Ramirez-Acuna JM, Perez-Romero BA,
Guerrero-Rodriguez JF, Martinez-Avila N and Martinez-Fierro ML: The
roles of matrix metalloproteinases and their inhibitors in human
diseases. Int J Mol Sci. 21:97392020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sisto M, Ribatti D and Lisi S: Cadherin
signaling in cancer and autoimmune diseases. Int J Mol Sci.
22:133582021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kryczka J, Kryczka J, Czarnecka-Chrebelska
KH and Brzezianska-Lasota E: Molecular mechanisms of
chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J
Mol Sci. 22:88852021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Mai H, Zhu Y, Li G, Sun J, Li G,
Liang B and Chen S: MicroRNA-4500 inhibits migration, invasion, and
angiogenesis of breast cancer cells via RRM2-dependent MAPK
signaling pathway. Mol Ther Nucleic Acids. 21:278–289. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khan P, Siddiqui JA, Kshirsagar PG,
Venkata RC, Maurya SK, Mirzapoiazova T, Perumal N, Chaudhary S,
Kanchan RK, Fatima M, et al: MicroRNA-1 attenuates the growth and
metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
Mol Cancer. 22:12023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zou Y, Zhou J, Xu B, Li W and Wang Z:
Ribonucleotide reductase subunit M2 as a novel target for
clear-cell renal cell carcinoma. Onco Targets Ther. 12:3267–3275.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shan J, Wang Z, Mo Q, Long J, Fan Y, Cheng
L, Zhang T, Liu X and Wang X: Ribonucleotide reductase M2 subunit
silencing suppresses tumorigenesis in pancreatic cancer via
inactivation of PI3K/AKT/mTOR pathway. Pancreatology. 22:401–413.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Y, Zhang Y, Li Q, Xu R and Huang N:
MiR-200c-3p and miR-485-5p overexpression elevates cisplatin
sensitivity and suppresses the malignant phenotypes of non-small
cell lung cancer cells through targeting RRM2. Thorac Cancer.
13:1974–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma X, Fu T, Ke ZY, Du SL, Wang XC, Zhou N,
Zhong MY, Liu YJ and Liang AL: MiR-17- 5p/RRM2 regulated
gemcitabine resistance in lung cancer A549 cells. Cell Cycle.
22:1367–1379. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang X, Li Y, Zhang N, Gao Y, Han L, Li
S, Li J, Liu X, Gong Y and Xie C: RRM2 silencing suppresses
malignant phenotype and enhances radiosensitivity via activating
cGAS/STING signaling pathway in lung adenocarcinoma. Cell Biosci.
11:742021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao X, Xue F, Chen H, Shen L, Yuan X, Yu
Y, Zong Y, Zhong L and Huang F: MiR-202-3p inhibits the
proliferation and metastasis of lung adenocarcinoma cells by
targeting RRM2. Ann Transl Med. 10:13742022. View Article : Google Scholar : PubMed/NCBI
|
